NEW DELHI: Aiming to ensure adequate stocks of
are available for hospitalised Covid-19 patients, the Centre has given fasttrack approval to
to ramp up production capacities to make around 78
per month, double the currently installed capacity of 38.8 lakh vials.
Manufacturers of Remdesivir have also agreed to voluntarily reduce the price to less than Rs 3,500 by the end of this week. At present, seven Indian companies are producing Injection Remdesivir under a licensing agreement with the American pharmaceutical company
, which holds the patent for the product.
“The current installed capacity of the seven manufacturers of Remdesivir is 38.8 lakh vials per month. Fasttrack approval has been given for seven additional sites having the production capacity of 10 lakh vials/month to six manufacturers. Another 30 lakh vials/month production is lined up. This would ramp up the production capacity for manufacturing to around 78 lakh vials/month,” the government said.
The decision was taken after a meeting this week between
, minister of state for chemicals & fertilisers, and all-existing manufacturers of the Remdesivir drug and other stakeholders.
Used for treating Ebola, the anti-viral drug has proven useful in the treatment of Covid-19 patients. However, the government has stressed that it is an ‘investigational drug’ and should be used only in hospital setting for Covid-19 patients on oxygen support. Health officials have strongly prohibited the use of the drug by patients at home.
The government has stopped the export of Remdesivir in the wake of rising Covid-19 cases across the country.